Home>Topics>Stocks>Idenix Pharmaceuticals

Idenix Pharmaceuticals IDIX

  1. All
  2. Commentary
  3. Headlines
    1. Former Merck analyst faces insider trading charges on merger tips

      Headlines

      Tue, 14 Oct 2014

      Co Inc employee with conspiracy to commit fraud for tipping a contact about potential mergers, including Merck's takeover of Idenix Pharmaceuticals ahead of a public announcement in June, according to a court filing on Tuesday.

    2. Why Did Baupost Double Its Stake In Keryx Biopharmaceuticals?

      Headlines

      Mon, 13 Oct 2014

      Seth Klarman and his fund have hit numerous 'homeruns,' like Micron Technology (NASDAQ: MU ) and Idenix Pharmaceuticals (NASDAQ: IDIX ). So what does this hedge fund manager extraordinaire see in Keryx (NASDAQ: KERX )? Chronic Kidney

    3. Achillion: Positioned To Deliver The Last Clinical Stage Nuc To The Highest Bidder

      Headlines

      Thu, 2 Oct 2014

      late entrants have lost significant time, leverage, and competitiveness since the Merck (NYSE: MRK )/Idenix (NASDAQ: IDIX ) acquisition this summer. We highlight Achillion (NASDAQ: ACHN ) as a top trade idea with our $34 DCF takeover valuation

    4. Achillion - An Options Strategy For A Potential Acquisition

      Headlines

      Mon, 8 Sep 2014

      By Small Pharma Analyst : A few months ago, Merck (NYSE: MRK ) surprised investors by acquiring Idenix (NASDAQ: IDIX ) for $3.85 billion, a 239% premium to its closing share price of the prior day. This was an unexpected acquisition

    5. Merck to buy Idenix for about $3.85 billion

      Headlines

      Mon, 9 Jun 2014

      June 9 (Reuters) - Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio.

    6. Idenix shares rise on promising mid-stage hep C data

      Headlines

      Wed, 20 Jun 2012

      (Reuters) - Shares of Idenix Pharmaceuticals Inc rose as much as 16 percent on Wednesday, after the company reported positive mid-stage trial data of its hepatitis C drug, suggesting it was closer...

    7. Dropping Coverage of Idenix

      Commentary

      Mon, 17 Aug 2009

      We are no longer providing equity research on Idenix Pharmaceuticals IDIX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    8. Idenix Advances Its HCV Pipeline

      Commentary

      Thu, 30 Jul 2009

      We're leaving our fair value estimate in place after reviewing the results from Idenix Pharmaceuticals ' IDIX three-day dose-escalation study for IDX184 in patients with genotype-1 hepatitis C. Idenix's share price plummeted following

    9. Another Quarter in Red for Idenix

      Commentary

      Tue, 5 May 2009

      We are maintaining our fair value estimate after reviewing Idenix Pharmaceuticals ' IDIX first-quarter results. Although this marked another quarter in the red for Idenix, the firm was able to increase revenue to

    10. Idenix Out-Licenses HIV Drug to Glaxo

      Commentary

      Fri, 6 Feb 2009

      We are maintaining our fair value estimate for Idenix Pharmaceuticals IDIX after the firm announced its decision to out-license its novel HIV treatment, IDX899, to GlaxoSmithKline GSK in order to focus

    « Prev123Next »
    Content Partners